Legacy, a male fertility company, has launched what it says is the first at-home semen analysis to deliver a complete clinical motility profile, including estimated initial motility, progressive motility, and post-thaw motility in a single workflow.
The company’s proprietary algorithm adjusts for the non-linear decline of motility over time, providing clinicians with a more reliable estimate of motility at the point of sample collection. The algorithm is based on peer-reviewed research published in the American Journal of Men’s Health.
“Our goal is simple: provide patients and clinicians with the most complete, reliable, and clinically actionable data possible,” said Khaled Kteily, CEO of Legacy. “This launch represents years of investment across lab science, kit engineering, logistics, and data modeling, letting clinicians trust Legacy results to guide care.”
Legacy says its process achieves a time to analysis of 20 hours compared to 28 hours or longer for competitors, resulting in 11% more preserved sperm motility – an outcome particularly relevant for intrauterine insemination (IUI) and IVF.
The company is also expanding its Provider Network, which currently includes over 400 clinics across the United States. The network serves IVF clinics, urologists, OB-GYNs, family practitioners, and complementary care providers, offering at-home sperm testing, DNA fragmentation testing, post-vasectomy semen analysis, and cryopreservation services.
“We believe it will help providers care for their patients, extend their brand reach, and increase patient engagement,” said Stephanie Sabourin, Legacy’s Director of Clinical Services.
